WhiteLab Genomics Presents In Vivo Data for AI-Designed Genomic Medicine Platform, Demonstrating Targeted Brain Delivery After IV Injection
New results suggest a potential path toward non-surgical genomic medicines for neurological diseases.
AI-Guided Engineering of rAAV Capsids: Overcoming Native Tropism Constraints for Precision In Vivo Gene Delivery
Our Global Director of Drug Design Dylan Serillon (PharmD, PhD) presents the latest in vivo results from WhiteLab's ALFRED platform. This work demonstrates what a fully rational, AI-guided rAAV engineering framework can achieve when built to simultaneously optimize receptor targeting, functional performance, and manufacturability rather than optimizing each in isolation.
The data reveals how structural and sequence-level multimodal modeling translates into measurable gains in tissue selectivity, transduction efficiency, and bioproduction scalability.
Meet Our Team in Boston
We'll be connecting with innovators throughout the event. Find us at the conference or book time with us below.
Discuss Delivery, Design & Manufacturing with Our Team
Beyond the oral presentation, our team will be available to discuss how ALFRED applies the same rational design logic across therapeutic contexts.
AAV Capsid Engineering
Rational, structure-guided capsid design to break native tropism constraints and achieve extra-hepatic targeting
Non-Viral Vectors
The same multimodal ALFRED framework applied to LNPs and polymer nanoparticles for precision payload delivery.
Payload Design
Modular, de novo cis-regulatory sequences engineered for cell-type specificity using single-cell epigenomic atlases and GRN inference.
Bioproduction
AI-guided optimization to improve vector yield and quality without sacrificing targeting gains — from design to scale.